Trade Report: Today: Sigma Planning Corp Buys 55 Shares of Diplomat Pharmacy Inc. (DPLO)

Today: Sigma Planning Corp Buys 55 Shares of Diplomat Pharmacy Inc. (DPLO)

Sigma Planning Corp raised its stake in Diplomat Pharmacy Inc. (NYSE:DPLO) by 0.3% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 18,761 shares of the company’s stock after buying an additional 55 shares during the period. Sigma Planning Corp’s holdings in Diplomat Pharmacy were worth $525,000 as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in the company. Moody Lynn & Lieberson LLC increased its position in Diplomat Pharmacy by 1.3% in the second quarter. Moody Lynn & Lieberson LLC now owns 15,105 shares of the company’s stock valued at $529,000 after buying an additional 190 shares during the period. Arizona State Retirement System boosted its stake in Diplomat Pharmacy by 1.6% in the second quarter. Arizona State Retirement System now owns 18,800 shares of the company’s stock valued at $658,000 after buying an additional 300 shares in the last quarter. PNC Financial Services Group Inc. boosted its stake in Diplomat Pharmacy by 5.1% in the third quarter. PNC Financial Services Group Inc. now owns 7,274 shares of the company’s stock valued at $203,000 after buying an additional 350 shares in the last quarter. Louisiana State Employees Retirement System boosted its stake in Diplomat Pharmacy by 2.5% in the second quarter. Louisiana State Employees Retirement System now owns 16,100 shares of the company’s stock valued at $564,000 after buying an additional 400 shares in the last quarter. Finally, RNC Capital Management LLC boosted its stake in Diplomat Pharmacy by 0.5% in the third quarter. RNC Capital Management LLC now owns 79,852 shares of the company’s stock valued at $2,237,000 after buying an additional 400 shares in the last quarter. 77.02% of the stock is currently owned by institutional investors.

Diplomat Pharmacy (NYSE:DPLO) last announced its quarterly earnings results on Wednesday, November 2nd. The company reported $0.21 EPS for the quarter, missing analysts’ consensus estimates of $0.24 by $0.03. The company earned $1.18 billion during the quarter, compared to the consensus estimate of $1.26 billion. Diplomat Pharmacy had a net margin of 0.77% and a return on equity of 10.47%. The business’s revenue was up 24.7% compared to the same quarter last year. During the same period last year, the company earned $0.26 earnings per share.

Several research firms recently commented on DPLO. Zacks Investment Research cut shares of Diplomat Pharmacy from a “buy” rating to a “hold” rating in a report on Thursday, August 11th. Avondale Partners cut shares of Diplomat Pharmacy from an “outperform” rating to a “market perform” rating in a report on Thursday, November 3rd. Leerink Swann cut shares of Diplomat Pharmacy from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $35.00 to $18.00 in a report on Thursday, November 3rd. TheStreet cut shares of Diplomat Pharmacy from a “hold” rating to a “sell” rating in a research note on Thursday, November 3rd. Finally, Credit Suisse Group AG reiterated a “hold” rating and issued a $18.00 target price on shares of Diplomat Pharmacy in a research note on Thursday, November 3rd. Three equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and two have given a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $26.00.

In other news, EVP Atheer A. Kaddis sold 20,000 shares of the company’s stock in a transaction dated Thursday, September 15th. The stock was sold at an average price of $30.12, for a total value of $602,400.00. Following the completion of the sale, the executive vice president now directly owns 20,000 shares of the company’s stock, valued at approximately $602,400. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 35.40% of the stock is owned by insiders.

About Diplomat Pharmacy

Diplomat Pharmacy, Inc operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy, and various other serious and/or long-term conditions.

Related posts

Leave a Comment